Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Dow
Moodys

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021259

See Plans and Pricing

« Back to Dashboard

NDA 021259 describes METADATE CD, which is a drug marketed by Lannett Co Inc and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the METADATE CD profile page.

The generic ingredient in METADATE CD is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
Summary for 021259
Tradename:METADATE CD
Applicant:Lannett Co Inc
Ingredient:methylphenidate hydrochloride
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021259
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259 NDA AUTHORIZED GENERIC Lannett Company, Inc. 0527-4579 0527-4579-37 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0527-4579-37)
METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259 NDA AUTHORIZED GENERIC Lannett Company, Inc. 0527-4580 0527-4580-37 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0527-4580-37)
Paragraph IV (Patent) Challenges for 021259
Tradename Dosage Ingredient NDA Submissiondate
METADATE CD CAPSULE, EXTENDED RELEASE;ORAL methylphenidate hydrochloride 021259 2007-03-15
METADATE CD CAPSULE, EXTENDED RELEASE;ORAL methylphenidate hydrochloride 021259 2005-05-13

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength20MG
Approval Date:Apr 3, 2001TE:AB2RLD:Yes
Patent:  Start TrialPatent Expiration:Oct 27, 2020Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength30MG
Approval Date:Jun 19, 2003TE:AB2RLD:Yes
Patent:  Start TrialPatent Expiration:Oct 27, 2020Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength10MG
Approval Date:May 27, 2003TE:AB2RLD:Yes
Patent:  Start TrialPatent Expiration:Oct 27, 2020Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Harvard Business School
McKesson
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.